Along with rising sales, GLP-1s are a major focus for R&D teams. Major pharma companies are developing new versions of the ...

When people feel dismissed, confused or misaligned with their healthcare experience, they often quietly disengage long before ...

CSL will pay $355M upfront to Alentis plus up to $1.2B milestones, while financing Phase II completion and Phase III in AAV-RPGN and Phase II programs in FSGS and PSC. Lixudebart targets claudin-1, ...

In today's Pharmaceutical Executive Daily, Foghorn Therapeutics and Eli Lilly discontinue development of FHD-909, their oral ...

Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest ...

FHD-909 is an oral, first-in-class allosteric small molecule selectively inhibiting SMARCA2 (BRM) ATPase over SMARCA4 (BRG1), both central catalytic subunits of BAF chromatin-remodeling complexes.

Real-world data from Novo's Octane study show patients who switched from injectable GLP-1 therapy to oral semaglutide lost an ...

Pharming CEO Fabrice Chouraqui has stepped down amid strategic disagreements with the board, with chief commercial officer Leverne Marsh and chief financial officer Kenneth Lynard now serving as ...

Truxon is EVP, Executive Director, Inclusive Health at Real Chemistry, a tier-one commercialization partner to the world's most innovative life sciences and healthcare companies. She founded the group ...

FDA broadened Camzyos use to symptomatic oHCM in adults and pediatric patients ≥30 kg, representing the first adolescent ...

Dr. Liang previously worked at Novo Nordisk, where he lead global clinical development and regulatory submission for ...